Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients With and Without Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: